Prelude Therapeutics Incorporated: Business Overview, Financials & Competitive Analysis
Prelude Therapeutics Incorporated scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage precision oncology company with differentiated degrader-based candidates and capital to advance multiple programs toward first-in-human studies. Prelude has initiated Phase 1 enrollment for its JAK2V617F program and is advancing PRT13722 toward IND filing. Recent capital raise provides runway, and preclinical data shows promise. However, as a clinical-stage company.
What is Prelude Therapeutics Incorporated's industry? Prelude Therapeutics Incorporated (preludetx.com) operates in Oncology Drugs. AskCyborg classifies Prelude Therapeutics Incorporated under Oncology Drugs in its company registry.
Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative targeted therapies for cancer patients. The company's portfolio includes PRT12396, a mutant-selective JAK2V617F inhi...
Cyborg Score thesis
Clinical-stage precision oncology company with differentiated degrader-based candidates and capital to advance multiple programs...
Read the full analyst-debate transcript →Get the Latest Prelude Therapeutics Incorporated Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreePrelude Therapeutics Incorporated Overview
Pro stress-test →Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative targeted therapies for cancer patients. The company's portfolio includes PRT12396, a mutant-selective JAK2V617F inhibitor in Phase 1 development for polycythemia vera and myelofibrosis, and PRT13722, a first-in-class, orally bioavailable, potent and selective KAT6A degrader for ER+/HER2- breast cancer.
Strategic Profile
Pro stress-test →The company is on track to file an IND for PRT13722 in mid-2026 and to start a Phase 1 clinical trial in H2 2026. In April 2026, Prelude raised $90.0 million in gross proceeds through an underwritten offering, positioning the company for clinical advancement of its lead programs. The company leverages expertise in targeted protein degradation to develop differentiated oncology therapies.
Competitive Landscape
Pro stress-test →Prelude operates in precision oncology with a focus on areas of high unmet need for cancer patients. The company competes with established pharma and biotechs developing protein degraders and targeted therapies. Key areas of competition include JAK2V617F inhibition for myeloproliferative neoplasms and KAT6A-targeted therapies for hormone receptor-positive breast cancer.
Industry Context
Prelude Therapeutics Incorporated operates in Oncology Drugs.
Key facts
Founded: 2014 · Headquarters: Wilmington, US · Employees: N/A · Revenue: $33.3M · Market cap: N/A